rs772887102
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_001350506.2(RARS2):c.-107T>G variant causes a 5 prime UTR premature start codon gain change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000397 in 1,613,180 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_001350506.2 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152234Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000220 AC: 55AN: 250154Hom.: 0 AF XY: 0.000177 AC XY: 24AN XY: 135220
GnomAD4 exome AF: 0.0000411 AC: 60AN: 1460946Hom.: 0 Cov.: 30 AF XY: 0.0000358 AC XY: 26AN XY: 726764
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152234Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74378
ClinVar
Submissions by phenotype
Pontocerebellar hypoplasia type 6 Pathogenic:5
- -
- -
- -
Compound heterozygous pathogenic variants, c.1612delA (p.T538fs) and c.419T>G (p.F140C), in the RARS2 gene were detected in this individual. The c.1612delA change predicts a translation reading frameshift at amino acid 538 (p.T538fs) with subsequent premature translation termination and therefore is classified as pathogenic. The c.419T>G (p.F140C) variant has been previously reported as disease causing [PMID 26795593, 25356970]. Whole exome sequencing and Sanger sequencing also showed that the mother is heterozygous for c.1612delA (p.T538fs) and the father is heterozygous for c.419T>G (p.F140C). Whole exome sequencing and Sanger sequencing also showed the affected sibling is heterozygous for both changes in RARS2. Our data indicate that the two changes in the RARS2 gene are in trans configuration (compound heterozygous) in this patient and the affected sibling. -
The c.419T>G (p.Phe140Cys) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. This variant has been previously reported as a compound heterozygous change in individuals with pontocerebellar hypoplasia (PMID: 25356970, 26795593, 30921410, 31216405, 38438854). The c.419T>G (p.Phe140Cys) variant is present in the heterozygous state in the gnomAD v4 population database at a frequency of 0.004% (64/1613180), and is absent in the homozygous state, thus is presumed to be rare. Based on the available evidence, c.419T>G (p.Phe140Cys) is classified as Pathogenic. -
not provided Pathogenic:2
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25356970, 26795593, 30921410, 31216405, 34717047, 37334785, 31160820, 38438854) -
This sequence change replaces phenylalanine, which is neutral and non-polar, with cysteine, which is neutral and slightly polar, at codon 140 of the RARS2 protein (p.Phe140Cys). This variant is present in population databases (rs772887102, gnomAD 0.2%). This missense change has been observed in individual(s) with clinical features of pontocerebellar hypoplasia and/or pontocerebellar hypoplasia (PMID: 26795593). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 215055). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt RARS2 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. -
Inborn genetic diseases Pathogenic:1
- -
Pontoneocerebellar hypoplasia Pathogenic:1
Variant summary: RARS2 c.419T>G (p.Phe140Cys) results in a non-conservative amino acid change located in the Arginyl-tRNA synthetase, catalytic core domain (IPR035684) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00022 in 250154 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in RARS2 causing Pontocerebellar Hypoplasia, Type 6 (0.00022 vs 0.0011), allowing no conclusion about variant significance. c.419T>G has been reported in the literature as a compound heterozygous genotype in individuals with features of RARS1-related disorders such as Pontocerebellar Hypoplasia, Type 6 and early-infantile (<12 weeks) developmental and epileptic encephalopathy undergoing Diagnostic Exome Sequencing (WES) analysis (example, Farwell_2015, Heiberg_2016, Liu_2019, de Valles-Ibanez_2022). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at